Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Novartis Boxes In Roche, Ups Ownership Stake To “Blocking Minority”

Executive Summary

Novartis is upping the pressure on Roche to negotiate a merger agreement - or face the threat of a veto by its Swiss neighbor on any strategic moves it undertakes

You may also be interested in...



Novartis Resumes Merger Search; Talks Up Schering, Ups Stake In Roche

Novartis is resuming its search for a merger partner, CEO Daniel Vasella indicated during the company's 2003 results conference Jan. 22 in Zurich

Novartis Resumes Merger Search; Talks Up Schering, Ups Stake In Roche

Novartis is resuming its search for a merger partner, CEO Daniel Vasella indicated during the company's 2003 results conference Jan. 22 in Zurich

Idenix/Novartis Telbivudine NDA Filing Slated For Late 2005, IPO Says

Idenix plans to file an NDA for the hepatitis B therapy telbivudine in late 2005, the Cambridge-based biotech company says in an initial public offering filed with the Securities & Exchange Commission Dec. 15

Latest Headlines
See All
UsernamePublicRestriction

Register

PS041162

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel